Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: exagamglogene autotemcel | Statement: [Vertex Pharmaceuticals, hasClinicalProgram, exagamglogene autotemcel]

Target entity: exagamglogene autotemcel
Context triple: [Vertex Pharmaceuticals, hasClinicalProgram, exagamglogene autotemcel]

• A. Kymriah
  Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
• B. onasemnogene abeparvovec
  Onasemnogene abeparvovec is a gene therapy medication that delivers a functional copy of the SMN1 gene to treat infants and young children with certain forms of spinal muscular atrophy.
• C. AveXis
  AveXis is a biotechnology company best known for developing the gene therapy onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy.
• D. daratumumab
  Daratumumab is a monoclonal antibody drug used primarily to treat multiple myeloma by targeting and destroying malignant plasma cells.
• E. isatuximab
  Isatuximab is a monoclonal antibody drug used primarily in the treatment of multiple myeloma by targeting and killing malignant plasma cells.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"

Entity: exagamglogene autotemcel
Triple: [Vertex Pharmaceuticals, hasClinicalProgram, exagamglogene autotemcel]

Exagamglogene autotemcel is an investigational CRISPR/Cas9-based gene-editing therapy being developed to treat inherited blood disorders such as sickle cell disease and transfusion-dependent beta thalassemia.

Target entity: exagamglogene autotemcel
Target entity description: Exagamglogene autotemcel is an investigational CRISPR/Cas9-based gene-editing therapy being developed to treat inherited blood disorders such as sickle cell disease and transfusion-dependent beta thalassemia.

• A. Kymriah
  Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
• B. onasemnogene abeparvovec
  Onasemnogene abeparvovec is a gene therapy medication that delivers a functional copy of the SMN1 gene to treat infants and young children with certain forms of spinal muscular atrophy.
• C. AveXis
  AveXis is a biotechnology company best known for developing the gene therapy onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy.
• D. daratumumab
  Daratumumab is a monoclonal antibody drug used primarily to treat multiple myeloma by targeting and destroying malignant plasma cells.
• E. isatuximab
  Isatuximab is a monoclonal antibody drug used primarily in the treatment of multiple myeloma by targeting and killing malignant plasma cells.
• F. None of above. chosen